Systemic therapies indicated for patients with completely resected stage III or IV melanoma in the adjuvant setting include the immuno-oncology (I-O) agents nivolumab and pembrolizumab, as well as the BRAF plus MEK inhibitor combination of dabrafenib plus trametinib (for BRAF-mutant disease) [1]. The gene discussed is BRAF; the disease is melanoma.